An experimental treatment for HD developed by Alnylam has shown long-lasting huntingtin lowering after just one dose, with encouraging early safety data. A pivotal trial is now planned for 2027 to figure out if this drug, brezosiran, can slow HD.

When someone with Huntington’s disease experiences new symptoms, is HD always the cause? Not necessarily. A new review explores catatonia, an uncommon condition that can cause changes that overlap with HD symptoms.

Scientists discovered a pocket on a protein called MSH3 that helps it grab DNA containing CAG repeats. By blocking this interaction, they slowed the growth of CAG repeats in cells, without removing the protein entirely.